ICER releases report on clinical effectiveness and value of immune-modulating ulcerative colitis therapies

Written by Ilana Landau, Editor

The Institute for Clinical and Economic Review (ICER; MA, USA) has released an Evidence Report concerning the comparative clinical effectiveness and value of eight targeted immune modulator therapies for the treatment of moderate–severe ulcerative colitis, a chronic inflammatory bowel condition. The report suggests that whilst these therapies likely provide significant benefits to individuals with ulcerative colitis, their prices exceed conventional cost–effectiveness thresholds. Ulcerative colitis is estimated to affect approximately 900,000 individuals across the USA; the disease results in long-lasting inflammation and ulceration of the digestive tract and is characterized by periods of symptom remission and recurrence. Pamela Bradt, Chief Scientific...

To view this content, please register now for access

It's completely free